Geron(GERN) Prnewswire·2025-04-25 09:45Core Viewpoint - Geron Corporation is facing a class action securities lawsuit due to alleged securities fraud related to the launch and growth potential of its drug Rytelo (imetelstat) between February 28, 2024, and February 25, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Geron misled investors regarding the expectations for Rytelo's market performance, downplaying risks associated with the drug's monitoring requirements and competition [2]. - Following the announcement of Geron's fourth-quarter financial results for fiscal 2024 on February 26, 2025, which revealed a flattening growth for Rytelo, the company's stock price dropped from 1.61 per share, a decline of approximately 32.07% in one day [2]. Group 2: Investor Information - Investors who suffered losses during the specified period have until May 12, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].